The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health ...

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...

23andMe is currently trading at around $3.15, down from more than $18 at the start of the year and more than $200 on its ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

Pelacarsen is in a cardiovascular outcomes trial in patients with elevated Lp (a) levels, with results expected in 2025, ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died, but that won't cause the study to be halted. The FDA has allowed the company ...